These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25080921)

  • 1. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.
    Hardwick RN; Clarke JD; Lake AD; Canet MJ; Anumol T; Street SM; Merrell MD; Goedken MJ; Snyder SA; Cherrington NJ
    Toxicol Sci; 2014 Nov; 142(1):45-55. PubMed ID: 25080921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.
    Kyriakides M; Hardwick RN; Jin Z; Goedken MJ; Holmes E; Cherrington NJ; Coen M
    Toxicol Sci; 2014 Nov; 142(1):105-16. PubMed ID: 25145655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
    Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH
    Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
    Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH
    Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.
    Wang Z; Zhou Q; Kruh GD; Gallo JM
    Drug Metab Dispos; 2011 Nov; 39(11):2155-61. PubMed ID: 21841039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
    Hardwick RN; Fisher CD; Street SM; Canet MJ; Cherrington NJ
    Drug Metab Dispos; 2012 Mar; 40(3):450-60. PubMed ID: 22112382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.
    Montonye ML; Tian DD; Arman T; Lynch KD; Hagenbuch B; Paine MF; Clarke JD
    J Pharmacol Exp Ther; 2019 Nov; 371(2):385-393. PubMed ID: 31420525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-by-Environment Interaction of Bcrp
    Toth EL; Li H; Dzierlenga AL; Clarke JD; Vildhede A; Goedken M; Cherrington NJ
    Drug Metab Dispos; 2018 Nov; 46(11):1478-1486. PubMed ID: 30166404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.
    Hardwick RN; Fisher CD; Canet MJ; Scheffer GL; Cherrington NJ
    Drug Metab Dispos; 2011 Dec; 39(12):2395-402. PubMed ID: 21878559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-Chronic Microcystin-LR Liver Toxicity in Preexisting Diet-Induced Nonalcoholic Steatohepatitis in Rats.
    Arman T; Lynch KD; Montonye ML; Goedken M; Clarke JD
    Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31323923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.
    Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Goedken MJ; Cherrington NJ
    Drug Metab Dispos; 2015 Feb; 43(2):266-72. PubMed ID: 25488932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
    Clarke JD; Hardwick RN; Lake AD; Canet MJ; Cherrington NJ
    J Pharmacol Exp Ther; 2014 Mar; 348(3):452-8. PubMed ID: 24403518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.
    Li H; Toth E; Cherrington NJ
    Toxicol Sci; 2018 Jan; 161(1):23-33. PubMed ID: 29145614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
    Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
    Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.
    Laho T; Clarke JD; Dzierlenga AL; Li H; Klein DM; Goedken M; Micuda S; Cherrington NJ
    Biochem Pharmacol; 2016 Sep; 115():144-51. PubMed ID: 27381944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.
    Cho SJ; Kim SB; Cho HJ; Chong S; Chung SJ; Kang IM; Lee JI; Yoon IS; Kim DD
    J Agric Food Chem; 2016 Jul; 64(27):5598-606. PubMed ID: 27321734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study.
    Luo G; Garner CE; Xiong H; Hu H; Richards LE; Brouwer KL; Duan J; Decicco CP; Maduskuie T; Shen H; Lee FW; Gan LS
    Drug Metab Dispos; 2007 Jun; 35(6):835-40. PubMed ID: 17332143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered arsenic disposition in experimental nonalcoholic fatty liver disease.
    Canet MJ; Hardwick RN; Lake AD; Kopplin MJ; Scheffer GL; Klimecki WT; Gandolfi AJ; Cherrington NJ
    Drug Metab Dispos; 2012 Sep; 40(9):1817-24. PubMed ID: 22699396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.
    Lickteig AJ; Fisher CD; Augustine LM; Aleksunes LM; Besselsen DG; Slitt AL; Manautou JE; Cherrington NJ
    Drug Metab Dispos; 2007 Oct; 35(10):1970-8. PubMed ID: 17640958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
    Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.